Nu Skin (NUS, $38.60) lowers earnings and sales outlook following China's scrutiny program on health products
Nu Skin Enterprises shares fell as much as -20% on Wednesday, after the company expressed concerns over headwinds from China’s increased scrutiny on health products.
The company, which develops and sells personal care products, revealed that it is adjusting its guidance for the year, mainly due to a dampened revenue outlook in Mainland China following the government’s 100-day campaign to review and scrutinize the health products and direct selling industries.
The increased scrutiny on the direct selling industry has reportedly led to a tightening of regulations on sales meetings - something that could adversely affect customer sentiment, as hinted by NU Skin CEO Ritch Wood. China accounted for 33% of Nu Skin’s revenue in 2018.
The company is scheduled to release its second quarter earnings reports on August 6. But as of now, Nu Skin is expecting its second-quarter earnings to range between 82 and 84 cents per share – down from its prior forecast of 91 to 98 cents per share. It now expects revenue between $622 million and $623 million, compared to its previous expectation of $660 million to $680 million.
Nu Skin has also lowered its full-year guidance. It now forecasts an earnings per share range of $3.20 to $3.35, compared to prior estimate of $3.80 to $4.05 a share. Its full year revenue expectation now sits between $2.48 billion to $2.52 billion, which is a range lower than its previous prediction of $2.76 billion to $2.81 billion.
NUS's RSI Indicator climbs out of oversold territory
The RSI Oscillator for NUS moved out of oversold territory on June 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In of the 41 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where NUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 16, 2026. You may want to consider a long position or call options on NUS as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NUS just turned positive on June 09, 2026. Looking at past instances where NUS's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NUS advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NUS entered a downward trend on July 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.320) is normal, around the industry mean (28.007). P/E Ratio (4.852) is within average values for comparable stocks, (56.142). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.959). Dividend Yield (0.046) settles around the average of (0.033) among similar stocks. P/S Ratio (0.182) is also within normal values, averaging (2.334).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of personal care products and nutritional supplements
Industry HouseholdPersonalCare
Advertisement